CEO's 'Actually Paid' Compensation Turns Negative in 2025 Amidst Worsening Financial Performance
RNAC sits 27% above its 52-week low of $5.6.
Summary
Cartesian Therapeutics' definitive proxy statement reveals a negative 'Compensation Actually Paid' for its CEO in 2025, largely due to a significant drop in equity award value, coinciding with an increased net loss for the company.
Key Events · Corporate Governance and Compliance · RNAC
-
Executive Compensation Reflects Performance Decline
The CEO's 'Compensation Actually Paid' for 2025 was negative $(633,791), a substantial decrease from $6.54 million in 2024, primarily due to a significant drop in the value of unvested equity awards.
-
Increased Net Loss Reported
The company reported a net loss of $130.3 million for 2025, a notable increase from $77.4 million in 2024, indicating worsening financial performance.
-
Routine Shareholder Proposals for Annual Meeting
The Annual Meeting on June 12, 2026, will address standard proposals including the election of three Class I Directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor.
-
Significant Insider Ownership
Director Timothy A. Springer holds a 33.3% beneficial ownership stake, and all executive officers, directors, and nominees as a group hold 37.2% of the outstanding common stock.
Analysis · RNAC · Life Sciences
This definitive proxy statement provides critical insights into Cartesian Therapeutics' financial health and executive incentives. The most striking revelation is the negative 'Compensation Actually Paid' for the CEO in 2025, primarily driven by a substantial decline in the value of unvested equity awards. This directly reflects the company's worsening financial performance, as evidenced by a significant increase in net loss for the year. While the Annual Meeting includes routine proposals, the compensation data signals a strong alignment of executive wealth with shareholder returns, highlighting the challenges the company faced in 2025. Investors should consider these compensation trends and the continued high insider ownership in evaluating the company's future prospects.
At the time of this filing, RNAC was trading at $7.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $187.9M. The 52-week trading range was $5.60 to $15.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.